Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature.
CDK 4/6 inhibitor
Palliative
Radiation recall
Radiotherapy
Toxicity
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
18
09
2020
accepted:
22
09
2020
pubmed:
24
11
2020
medline:
24
11
2020
entrez:
23
11
2020
Statut:
ppublish
Résumé
Current first-line systemic treatment in most patients with metastatic hormone receptor-positive, HER-2 negative breast cancer is an aromatase inhibitor in combination with a cyclin dependant kinase (CDK) 4/6 inhibitor. Frequently, these patients require palliative radiotherapy (RT) for symptomatic disease management. There is a paucity of data on the safety of combining a CDK 4/6 inhibitor with palliative RT, with conflicting case reports in the literature. We report on 5 cases at our institution where enhanced radiotherapy toxicity was observed when palliative doses of RT was delivered during or prior to treatment with a CDK 4/6 inhibitor. After review of pre-clinical and mechanistic data, we hypothesise that the effects of CDK4/6 inhibition on normal tissue and the tumour microenvironment may impede tissue recovery and exacerbate acute radiation and radiation recall toxicities. Further studies are required to clarify the potential toxicities of this combination. Clinicians should consider the potential risks when combining CDK 4/6 inhibitors with palliative RT and individualise patient management accordingly.
Identifiants
pubmed: 33227663
pii: S1936-5233(20)30431-9
doi: 10.1016/j.tranon.2020.100939
pmc: PMC7689545
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100939Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.
Références
Cancer Cell. 2018 Jul 9;34(1):9-20
pubmed: 29731395
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
Cell Death Discov. 2017 Jul 03;3:17033
pubmed: 28690875
Genetics. 2013 Apr;193(4):1025-64
pubmed: 23547164
Front Immunol. 2017 May 26;8:613
pubmed: 28603525
Rep Pract Oncol Radiother. 2019 May-Jun;24(3):276-280
pubmed: 30948930
Oncologist. 2010;15(11):1227-37
pubmed: 21045191
Breast. 2018 Dec;42:1-2
pubmed: 30118901
J Neurooncol. 2019 Sep;144(3):583-589
pubmed: 31399935
Ann Oncol. 2018 Jul 1;29(7):1541-1547
pubmed: 29718092
Breast. 2019 Aug;46:70-74
pubmed: 31100573
Breast Cancer Res. 2016 Feb 09;18(1):17
pubmed: 26857361
Radiother Oncol. 2019 Feb;131:240-241
pubmed: 30336956
Oncogene. 2007 Feb 22;26(8):1101-9
pubmed: 16924237
Oncogene. 2013 Nov 28;32(48):5481-91
pubmed: 23708653
Sci Rep. 2016 Jun 01;6:27043
pubmed: 27245205
Cancer Discov. 2018 Feb;8(2):216-233
pubmed: 29101163
J Clin Invest. 2016 Nov 1;126(11):4076-4087
pubmed: 27701148
Biochim Biophys Acta. 2000 Feb 14;1470(1):M1-12
pubmed: 10656985
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Cell Rep. 2018 Mar 13;22(11):2978-2994
pubmed: 29539425
Adv Radiat Oncol. 2019 Apr 03;4(3):453-457
pubmed: 31360799
Breast Cancer Res. 2008;10(5):R75
pubmed: 18782450
JAMA Oncol. 2019 Sep 29;:
pubmed: 31563959
Semin Oncol. 2017 Dec;44(6):385-394
pubmed: 29935900
Front Mol Biosci. 2014 Nov 17;1:24
pubmed: 25988165